The Time to Transform Healthcare is Now
Immersive Digital Therapeutics are changing the healthcare delivery system with evidence-based technologies that are intended to improve patient outcomes. Sign our petition to help support the successful passing of the Access to Prescription Digital Therapeutics Act of 2023 (S. 723/H.R. 1458).
“Over the last 15 years, we’ve been exploring ways to use immersive technology to improve quality of life for those facing a wide array of psychiatric and neurological conditions... I am excited about the next frontier of VR-based, clinical research and how these digital prescriptions of the future may benefit aging adults and their caregivers."
Adam Gazzaley, MD, Ph.D.
Founder/Executive Director, Neuroscape
Advancement of Immersive,
Digital Therapeutics in the U.S.
The Access to Prescription Digital Therapeutics Act of 2023 (S. 723/H.R. 1458) aims to officially define prescription digital therapeutics (PDTs) at the federal level and establish new payor benefit categories for PDTs. A growing class of treatments, PDTs are software-based therapies that deliver a clinical benefit to patients, either alone or in combination with other treatments.
The bi-partisan, bi-cameral bill was introduced on March 8, 2023 by Senators Jeanne Shaheen (D-NH), Shelley Moore Capito (R-WV), Marsha Blackburn (R-TN), and Cory Booker (D-NJ) and Representatives Kevin Hern (R-OK), Mike Thompson (D-CA), Bill Johnson (R-OH), and Doris Matsui (D-CA). If passed, it could improve healthcare access for more than 148 million Americans.
Earlier versions of the legislation (S. 3791/H.R. 7051) were introduced in the 117th Congress by a bipartisan coalition led by Senators Shelley Moore Capito (R-WV) and Jeanne Shaheen (D-NH) and Representatives Mike Thompson (D-CA) and David McKinley (R-WV). The current version of the bill is identical to language from the 117th Congress, apart from new dates for implementation.
Sign our petition to support the successful passing of the Access to Prescription Digital Therapeutics Act of 2023 and help improve clinical and health outcomes for older adults in the U.S.:
For the full bill text, please click here.
“The bill will allow more patients living with a variety of diseases and conditions from Opioid Use Disorders to diabetes to Parkinson’s disease to more efficiently access the care and support they need and deserve.”
Senator Shelley Capito (R–WV)
The Value of PDTs
Digital therapeutic tools include screen devices such as smartphones, tablets, computers, VR headsets, and videogame platforms that converge with software algorithms. Together, these can be applied to improve therapy management and rehabilitation. They are used independently or in concert with medications, devices, or other therapies to optimize patient care and health outcomes.
PDTs are designed and tested much like traditional prescription drugs but rather than swallowing a pill or taking an injection, patients receive cognitive therapy through software. The treatments are tested for safety and efficacy in randomized clinical trials, evaluated by the U.S. Food and Drug Administration (FDA) and prescribed by health care providers.
Sign our petition to support the successful passing of the Access to Prescriptive Digital Therapeutics Act of 2023 and help improve clinical and health outcomes for older adults in the U.S.:
The Role of Digital Therapeutics and the Changing Future of Healthcare – NIH Link
“Our bill ensures these prescription digital therapeutics are covered by Medicare so more patients, including seniors, have access to the cutting-edge care they deserve."
Senator Jeanne Shaheen (D–NH)
Sign our Petition
Fill out and submit the form below to support the successful passing of the Access to Prescriptive Digital Therapeutics Act of 2023 and help provide access to an impressive array of therapeutic interventions that improve clinical and health outcomes for our aging population.
“I've made self-directed efforts to use VR for my own personal well-being. Everything from mindfulness to pain/stress relief and patient distraction during time-consuming procedures. This Act will support efforts to make these therapies widespread."